In a report released on March 31, Christophe dombu from Kepler Capital maintained a Buy rating on Hyloris Pharmaceuticals SA (52U – Research Report), with a price target of €16.00. The company’s shares closed last Friday at €5.90.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, dombu is an analyst with an average return of -7.2% and a 38.10% success rate.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Hyloris Pharmaceuticals SA with a €16.00 average price target.
52U market cap is currently €171.4M and has a P/E ratio of -25.43.
Read More on DE:52U:
- Hyloris Pharmaceuticals Reports Strong 2024 Results and Strategic Progress
- Hyloris Pharmaceuticals Receives Positive IDMC Recommendation for Alenura Trial
- Hyloris Pharmaceuticals Expands Pipeline with Ready-To-Use Pantoprazole IV
- Hyloris Pharmaceuticals Reports Positive Study Results for Dofetilide IV
- Hyloris’ Valacyclovir Oral Suspension NDA Accepted by FDA